Premium
Bone marrow stromal cells protect oligodendrocytes from oxygen‐glucose deprivation injury
Author(s) -
Zhang Jing,
Li Yi,
Zheng Xuguang,
Gao Qi,
Liu Zhongwu,
Qu Runjiang,
Borneman Jade,
Elias Stanton B.,
Chopp Michael
Publication year - 2008
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.21617
Subject(s) - protein kinase b , pi3k/akt/mtor pathway , oligodendrocyte , biology , stromal cell , microbiology and biotechnology , ly294002 , cancer research , immunology , chemistry , phosphorylation , signal transduction , neuroscience , central nervous system , myelin
Oligodendrocyte (OLG) damage leads to demyelination, which is frequently observed in ischemic cerebrovascular diseases. In this study, we investigated the effect of bone marrow stromal cells (BMSCs) on OLGs subjected to oxygen‐glucose deprivation (OGD). N20.1 cells (mouse OLG cell line) were transferred into an anaerobic chamber for 3 hr in glucose‐free and serum‐free medium. After OGD incubation, OLG cultures were divided into the following groups: 1) OGD alone, 2) OLG cocultured with BMSCs, 3) treatment with the phosphoinostide 3‐kinase (PI3k) inhibitor LY294002, 4) LY294002‐treated OLGs with BMSC cocultured, and 5) anti‐p75 antibody‐treated OLGs. After an additional 3 hr of reoxygenation incubation, OLG viability and apoptosis were measured. The mRNA expression in the BMSCs and OLGs was analyzed using quantitative real‐time PCR (RT‐PCR). Serine/threonine‐specific protein kinase (Akt), phosphorylated Akt (p‐Akt), p75, and caspase 3 protein expressions in OLGs were measured by Western blot. Our results suggest that BMSCs produce growth factors, activate the Akt pathway, and increase the survival of OLGs. BMSCs also reduce p75 and caspase 3 expressions in the OGD‐OLGs, which leads to decreased OLG apoptosis. BMSCs participate in OLG protection that may occur with promoting growth factors/PI3K/Akt and inhibiting the p75/caspase pathways. Our study provides insight into white matter damage and the therapeutic benefits of BMSC‐based remyelinating therapy after stroke and demyelinating diseases. © 2008 Wiley‐Liss, Inc.